Targeted blocking of miR328 lysosomal degradation with alkalized exosomes sensitizes the chronic leukemia cells to imatinib

Imatinib resistance remains the biggest hurdle for the treatment of chronic myeloid leukemia (CML), with the underlying mechanisms not fully understood. In this study, we found that miR328 significantly and strikingly decreased among other miRNA candidates during the induction of imatinib resistance. Overexpression of miR328 sensitized resistant cells to imatinib via post-transcriptionally decreasing ABCG2 expression, while miR328 knockdown conferred imatinib resistance in parental K562 cells. Moreover, miR328 was found selectively degraded in the lysosomes of K562R cells, as inhibition of lysosome with chloroquine restored miR328 expression and increased sensitivity to imatinib. Moreover, delivery of alkalized exosomes increased endogenous miR328 expression. Compared with the corresponding controls, the alkalized exosomes with or without miR328 sensitized the chronic leukemia cells to imatinib. Taken together, our study has revealed that lysosomal clearance of miR328 in imatinib-resistant cells at least partially contributes to the drug resistance, while delivery of alkalized exosomes would sensitize the chromic leukemia cells to imatinib.

[1]  G. Daley,et al.  Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL , 2003, Cell.

[2]  W. Dunn,et al.  Autophagy and related mechanisms of lysosome-mediated protein degradation. , 1994, Trends in cell biology.

[3]  L. Doyle,et al.  Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.

[4]  X. Li,et al.  Transcriptional regulation of mammalian miRNA genes. , 2011, Genomics.

[5]  Hans Clevers,et al.  The cancer stem cell: premises, promises and challenges , 2011, Nature Medicine.

[6]  Kathryn A. O’Donnell,et al.  c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.

[7]  Frank Speleman,et al.  miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis , 2010, Nature Cell Biology.

[8]  S. Jhanwar,et al.  Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS). , 2016, Leukemia research.

[9]  Edurne San José-Enériz,et al.  MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations , 2009, Molecular Cancer.

[10]  J. Apperley Chronic myeloid leukaemia , 2015, The Lancet.

[11]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[12]  Marilyn E Morris,et al.  MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells , 2009, Molecular Pharmacology.

[13]  Quentin Liu,et al.  Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation , 2016, Scientific Reports.

[14]  Sha Li,et al.  Exosome and Exosomal MicroRNA: Trafficking, Sorting, and Function , 2015, Genom. Proteom. Bioinform..

[15]  D. Gilliland,et al.  Leukemia stem cells. , 2010, Seminars in cancer biology.

[16]  P. Doležel,et al.  Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells. , 2014, Chemico-biological interactions.

[17]  B. Druker,et al.  Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. , 2003, Blood.

[18]  L. Hu,et al.  Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant , 2010, British Journal of Cancer.

[19]  Tania Nolan,et al.  Quantification of mRNA using real-time RT-PCR , 2006, Nature Protocols.

[20]  K. Bhalla,et al.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. , 2007, Blood.

[21]  A. Whitehead,et al.  The 3′ Untranslated Region of the Membrane-Bound IL-1R Accessory Protein mRNA Confers Tissue-Specific Destabilization , 2004, The Journal of Immunology.

[22]  Gunther Hartmann,et al.  SiRNA delivery with exosome nanoparticles , 2011, Nature Biotechnology.

[23]  Michael R. Green,et al.  A therapeutically targetable mechanism of BCR-ABL–independent imatinib resistance in chronic myeloid leukemia , 2014, Science Translational Medicine.

[24]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[25]  M. Noble,et al.  Cancer stem cells. , 2006, The New England journal of medicine.

[26]  H. Grosshans,et al.  MicroRNA turnover: when, how, and why. , 2012, Trends in biochemical sciences.

[27]  A. van den Berg,et al.  MicroRNAs, macrocontrol: regulation of miRNA processing. , 2010, RNA.

[28]  H. Kantarjian,et al.  Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy , 2012, Cancer.

[29]  B. Druker,et al.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. , 2011, The Journal of clinical investigation.

[30]  J. Melo,et al.  MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. , 2003, Blood.

[31]  G. Hannon,et al.  A MicroRNA Feedback Circuit in Midbrain Dopamine Neurons , 2007, Science.

[32]  A. Hata,et al.  Regulation of MicroRNA Biogenesis: A miRiad of mechanisms , 2009, Cell Communication and Signaling.

[33]  F. Sánchez‐Madrid,et al.  ISGylation controls exosome secretion by promoting lysosomal degradation of MVB proteins , 2016, Nature Communications.

[34]  K. Wada,et al.  Lysosomal putative RNA transporter SIDT2 mediates direct uptake of RNA by lysosomes , 2016, Autophagy.

[35]  T. Litman,et al.  Regulation of ABCG2 Expression at the 3′ Untranslated Region of Its mRNA through Modulation of Transcript Stability and Protein Translation by a Putative MicroRNA in the S1 Colon Cancer Cell Line , 2008, Molecular and Cellular Biology.

[36]  Eeva-Liisa Eskelinen,et al.  Autophagy: a lysosomal degradation pathway with a central role in health and disease. , 2009, Biochimica et biophysica acta.

[37]  Guodong Yang,et al.  Semi-random mutagenesis profile of BCR-ABL during imatinib resistance acquirement in K562 cells , 2017, Molecular medicine reports.

[38]  W. Filipowicz,et al.  The widespread regulation of microRNA biogenesis, function and decay , 2010, Nature Reviews Genetics.

[39]  I. Cascorbi,et al.  MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression , 2012, Pharmacogenetics and genomics.

[40]  M. Talpaz,et al.  Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia , 2011, Leukemia.

[41]  Tsung-Cheng Chang,et al.  Widespread microRNA repression by Myc contributes to tumorigenesis , 2008, Nature Genetics.

[42]  B. Aggarwal,et al.  Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia , 2004, Cancer Research.

[43]  S. Emr,et al.  Autophagy as a regulated pathway of cellular degradation. , 2000, Science.

[44]  J. Radich,et al.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. , 2008, Blood.

[45]  M. Dean,et al.  Multidrug Efflux Pumps and Cancer Stem Cells: Insights Into Multidrug Resistance and Therapeutic Development , 2011, Clinical pharmacology and therapeutics.

[46]  K. Wada,et al.  Lysosomal degradation of intracellular nucleic acids-multiple autophagic pathways. , 2016, Journal of biochemistry.

[47]  M. Fabbri,et al.  MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications , 2008, Leukemia.

[48]  M. Caligiuri,et al.  miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts , 2010, Cell.

[49]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.